Green Thumb Industries Inc banner
G

Green Thumb Industries Inc
CNSX:GTII

Watchlist Manager
Green Thumb Industries Inc
CNSX:GTII
Watchlist
Price: 10.03 CAD 8.55% Market Closed
Market Cap: CA$2.3B

EV/OCF

5.5
Current
42%
Cheaper
vs 3-y average of 9.4

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
5.5
=
Enterprise Value
CA$2.1B
/
Operating Cash Flow
$294.9m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
5.5
=
Enterprise Value
CA$2.1B
/
Operating Cash Flow
$294.9m

Valuation Scenarios

Green Thumb Industries Inc is trading below its 3-year average

If EV/OCF returns to its 3-Year Average (9.4), the stock would be worth CA$17.16 (71% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+205%
Average Upside
139%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 5.5 CA$10.03
0%
3-Year Average 9.4 CA$17.16
+71%
5-Year Average 11.8 CA$21.65
+116%
Industry Average 14.4 CA$26.39
+163%
Country Average 16.7 CA$30.57
+205%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
US
Green Thumb Industries Inc
CNSX:GTII
2.1B CAD 5.5 14.6
US
Eli Lilly and Co
NYSE:LLY
835.2B USD 51.6 40.5
US
Johnson & Johnson
NYSE:JNJ
547.8B USD 23.4 26
CH
Roche Holding AG
SIX:ROG
248.4B CHF 15.2 20.1
UK
AstraZeneca PLC
LSE:AZN
216.4B GBP 21.1 28
CH
Novartis AG
SIX:NOVN
223.1B CHF 15.2 19.5
US
Merck & Co Inc
NYSE:MRK
276.9B USD 18.8 15.2
IE
Endo International PLC
LSE:0Y5F
244.4B USD 936 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 10.5 11.4
US
Pfizer Inc
NYSE:PFE
153.5B USD 17.2 19.8
US
Bristol-Myers Squibb Co
NYSE:BMY
118.2B USD 10.6 16.8
P/E Multiple
Earnings Growth PEG
US
G
Green Thumb Industries Inc
CNSX:GTII
Average P/E: 21.2
14.6
-21%
N/A
US
Eli Lilly and Co
NYSE:LLY
40.5
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
CH
Novartis AG
SIX:NOVN
19.5
14%
1.4
US
Merck & Co Inc
NYSE:MRK
15.2
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.8
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.8
16%
1

Market Distribution

Lower than 93% of companies in the United States of America
Percentile
7th
Based on 9 518 companies
7th percentile
5.5
Low
0 — 11.7
Typical Range
11.7 — 23.6
High
23.6 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 11.7
Median 16.7
70th Percentile 23.6
Max 3 178 983.5

Green Thumb Industries Inc
Glance View

Green Thumb Industries Inc., a notable player in the U.S. cannabis industry, operates like a well-tuned orchestra, harmonizing various elements of the cannabis business. The Chicago-based company is vertically integrated, meaning it controls each aspect of its product lifecycle—from cultivation to distribution. This structure enables Green Thumb to maintain consistency in its product quality while maximizing its operational efficiency. At the heart of its business model lies a diverse portfolio of well-regarded cannabis brands that cater to different consumer segments, from high-end connoisseurs to medicinal users seeking relief. These brands, including RYTHM, Dogwalkers, and Beboe, are strategically distributed across its extensive network of retail outlets, known as RISE dispensaries, as well as through wholesale channels. Like a savvy trader on a bustling market floor, Green Thumb’s profitability hinges on its ability to enhance scale while navigating the complex regulatory landscape. In each state where it operates, the company must tailor its approach to meet varying levels of regulation and market maturity. This agility provides Green Thumb with a competitive edge, allowing it to efficiently expand in both medical and adult-use markets while adhering to legal standards. The company generates revenue not only from its direct-to-consumer sales through dispensaries but also through wholesale transactions with other cannabis retailers. By maintaining robust relationships across these segments, Green Thumb underscores its position as a cornerstone of the cannabis industry's growth narrative.

GTII Intrinsic Value
12.53 CAD
Undervaluation 20%
Intrinsic Value
Price CA$10.03
G
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett